CrowdStrike has navigated the June 17 catalyst and is trading at $679.49 — up 5.4% on the week but down nearly 2% on Tuesday — with the pre-event defensiveness that dominated this column for ten days now giving way to a more straightforward valuation debate.
The options story that led every note heading into June 17 has begun to unwind. The put/call ratio, which had been above 1.0 for eight consecutive sessions and running nearly 1.4 standard deviations above its 20-day mean, closed at 1.02 on June 16 — still modestly elevated but no longer at the year's defensive extreme. The 20-day mean itself is drifting up toward 0.98, compressing the z-score to 0.91. The urgency that characterized the pre-event hedging flow has eased; what remains is a market that is mildly cautious rather than braced for impact. On the lending side, the picture is unambiguously loose. Availability has surged to roughly 8,777% — meaning there are nearly 88 shares available to borrow for every one currently shorted — the widest reading of the past month and well above the 52-week trough near 1,980%. Short interest itself is a non-story at just under 3% of free float, fractionally higher on the week and essentially flat over the past month. Cost to borrow has nudged up 6% over the week to 0.45% but remains inconsequentially low. There is no squeeze pressure, no crowding, and no borrow tightness to speak of.
The Street's positioning after the June 4 analyst wave is where the more interesting tension lives. Almost every firm raised targets sharply on June 4 — Morgan Stanley to $690, UBS to $790, Citi to $780, BofA to $750 — yet the stock at $679 is still trading below Morgan Stanley's revised number and comfortably below the consensus mean of $712. The bull case rests on platform consolidation, AI-powered threat detection stickiness, and what the company's own guidance described as consistent beats on ARR and free cash flow. The bear case is more structural: competition from Microsoft and SentinelOne, the shadow of the July 2024 outage as a recurring risk template, and a valuation that remains demanding at roughly 84x EV/EBITDA and 123x trailing earnings. Bernstein's Market Perform at $413 and BNP Paribas Neutral at $520 still sit well below current levels, anchoring the skeptic camp. The forward EPS growth story remains exceptional — the 12-month forward year-on-year increase ranks in the 95th percentile across the universe — but that growth is already priced in at current multiples, and the earnings yield at 0.81% leaves little room for disappointment.
CEO George Kurtz sold approximately $1 million in stock across multiple tranches on June 12, the week's only notable insider activity. The individual sales were small — the largest single tranche was 300 shares at $682.98 — and all carried a low significance score of 2 out of 10, suggesting routine plan-driven disposals rather than a directional signal. The 90-day net insider position is marginally positive at roughly 5,300 shares, so there is no sustained distribution trend to read into. Still, the timing — into the stock's recovery from its post-earnings floor near $645 and just before the June 17 event — is worth noting as context. Closest peer PANW gained 7.4% on the week while RBRK fell 3.6%, underscoring that the cybersecurity tape remains stock-specific rather than sector-uniform.
The next scheduled event is August 25. Between now and then, the debate narrows to whether the stock can close the gap to the $712 consensus mean — roughly 4.8% from current levels — or whether the pattern of post-event selling that produced a 6.5% drop after the June 3 print and a further 16% peak-to-trough drawdown reasserts itself on any fresh disappointment.
See the live data behind this article on ORTEX.
Open CRWD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
